Clinical uses of tumor markers: A critical review

Critical Reviews in Clinical Laboratory Sciences

Volumn 38, Issue 3, 2001, Pages 225-262

  Duffy, M J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cancer; Diagnosis; Monitoring; Prediction; Prognosis; Review; Screening; Tumor markers

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UROKINASE;

CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GERM CELL TUMOR; HORMONE SENSITIVITY; OVARY CARCINOMA; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; REVIEW; TROPHOBLASTIC DISEASE; ULTRASOUND;

EID: 0034968363     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/20014091084218     Document Type: Review

References (129)

1. Preoperative carcinoembryonic antigen as a prognostic indicator in colorectal cancer
2. CA 15-3 and related mucins as circulating markers in breast cancer
3. Tumour-associated antigens
4. The CA 125 tumour-associated antigen: A review of the literature
5. CA 19-9 as a marker of gastrointestinal cancers: A review
6. The clinical significance of human alpha-fetoprotein
7. Hormone production by tumors: Biological and clinical aspects
8. CEA, AFP and other tumor markers
9. Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls
10. Guidance on terminology
11. Screening for cancer and pre-cancer
12. Should we be screening for colorectal cancer?
13. Limitations of tumour markers in screening
14. Cancer incidence, survival and mortality in children under 15 years of age
15. Is neuroblastoma screening evaluation needed and feasible?
16. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society workshop on neuroblastoma screening
17. A population-based study on the usefulness of screening for neuroblastoma
18. Estimates of the worldwide incidence of 25 major cancers in 1990
19. Cancer statistics
20. Defining and updating the American Cancer Society guidelines for cancer related checkup
21. American Cancer Society guidelines for the early detection of prostate cancer
22. PSA screening for prostate cancer
23. Prostate cancer diagnosis and management
24. Prostate cancer screening: Practice what the evidence preaches
25. Prostate-specific antigen: Biochemistry, analytical methods and clinical application
26. Prostate-specific antigen: Update 1997
27. PSA as a marker for prostate cancer
28. The effects of prostate manipulation on prostate-specific antigen levels
29. The effect of prostatitis, urinary retention, ejaculation and ambulation on the serum prostate-specific antigen concentration
30. Influence of investigative and operative procedures on serum prostate-specific antigen concentration
31. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: Assay of the complex improves clinical sensitivity for cancer
32. Human kallikrein 2 (hK2) and prostate-specific antigen: Two closely related, but distinct kallikreins in the prostate
33. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men
34. The results of prostate cancer screening in the U.S. as reflected in the surveillance, epidemiology and end result program
35. European randomized study of prostate cancer screening: First year results of the Finnish trial
36. Early detection of prostate cancer. I. Prior probability and effectiveness of test
37. Positive predictive value of screening mammography by age and family history of breast cancer
38. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
39. Epithelial ovarian carcinoma
40. Ovarian cancer: Screening, treatment and follow-up
41. The performance of screening tests for ovarian cancer: Results of a systematic review
42. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
43. Clinical application of serum tumor markers
44. OVX1 radioimmunoassay complements CA 125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance
45. Towards an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
46. Hepatocellular carcinoma
47. Early detection of hepatocellular carcinoma
48. The increasing incidence of hepatocellular carcinoma
49. Screening for hepatocellular carcinoma in high risk individuals, a clinical review
50. The use of potential of serum tumor markers, new and old
51. Detection of cancer by tumor markers in the blood: A view to the future
52. Early detection of primary hepatocellular carcinoma: Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus
53. Tumor markers in gastrointestinal cancer, EGTM recommendations
54. Tumor markers, where do we go from here?
55. Gestational trophoblasfic disease and their treatment
56. RET gene and its implications for cancer
57. Medullary thyroid carcinoma
58. Medullary thyroid carcinoma, genes and prevention of cancer
59. Results of a screening program for c-cell disease (medullary thyroid cancer and c-cell hyperplasia)
60. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
61. Usefulness of tumor markers
62. The clinical utility of CA 19-9
63. Diagnostic value of pelvic examination, ultrasound and serum CA 125 in post-menopausal women with a pelvic mass
64. Use of tumor markers to identify primary site of metastatic cancer
65. Metastasis of unknown primary site
66. How shall we apply the new biology to diagnostics in surgical pathology
67. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma
68. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
69. Prognostic and predictive markers in cancer
70. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers
71. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors
72. Tumor markers at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer
73. Prostate cancer: A current perspective
74. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
75. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer
76. Biological determinants of cancer progression in men with prostate cancer
77. The clinical value of tumour markers in the management of ovarian cancer
78. CA 125: The past and the future
79. Carcinoembryonic antigen
80. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract
81. Preoperative serum levels of CA242 and CEA predict outcome in colorectal cancer
82. Preoperative CA 15-3 concentrations predict outcome of patients with breast cancer
83. CA 15-3, a circulating marker with strong prognostic value in breast cancer, new observation
84. Estrogen receptor as an independent prognostic factor for early recurrences in breast cancer
85. Biochemical markers as prognostic indices in breast cancer
86. Time-dependence of hazard ratios for prognostic factors in primary breast cancer
87. Estrogen receptor β: Reevaluation of estrogen and antiestrogen signaling
88. The erbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
89. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
90. ErbB-2 oncogene in human breast cancer and its clinical significance
91. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
92. Biological and clinical importance of the p53 tumor suppressor gene
93. Prognostic and predictive value of p53 and p21 in breast cancer
94. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients
95. Association of p53 protein expression with tumor cell proliferation and clinical outcome in node-negative breast cancer
96. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
97. Prognostic significance of p53 gene alterations in node-negative breast cancer
98. The biochemistry of metastasis
99. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
100. Interim analysis of a randomized trial on risk-adapted adjuvant chemotherapy in node-negative breast cancer patients guided by the prognostic factors uPA and PAI-1
101. The urokinase-type plasminogen activator system in cancer metastasis
102. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
103. Cathepsin in breast cancer: A tissue marker associated with metastasis
104. Cathepsin D and breast cancer
105. Steroid hormone receptors in breast cancer treatment strategy
106. Tamoxifen for early breast cancer: An overview of randomized trials
107. HER-2/neu as a predictive marker of response to breast cancer therapy
108. HER-2/neu (c-erbB-2) gene and protein in breast cancer
109. Should HER2 status be routinely measured for all breast cancer patients
110. Apoptosis and therapy
111. Predicting response to cancer chemotherapy: The role of p53
112. CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer
113. An evaluation of the carcinoembryonic antigen (CEA) for monitoring patients with resected colon cancer
114. The value of carcinoembryonic antigen measurement in clinical practice
115. Follow-up of colorectal cancer: A meta-analysis
116. Follow-up of patients with colorectal cancer, a meta-analysis
117. Surgical experience with hepatic colorectal metastasis
118. Natural history of progression after PSA elevation following radical prostatectomy
119. Consensus statement: Guidelines for PSA following radiation therapy
120. Tumour markers in patients on deferred treatment: Prostate specific antigen doubling times
121. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer
122. CA 125 in ovarian cancer
123. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
124. Use of tumor markers in monitoring the course of ovarian cancer
125. Detection of tumor messenger RNA in serum of patients with malignant melanoma
126. A prospective study of k-ras mutations in the plasma of pancreatic cancer patients